1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Brain Tumor - Pipeline Review, H1 2014

Brain Tumor - Pipeline Review, H1 2014

  • February 2014
  • -
  • Global Markets Direct
  • -
  • 80 pages

Brain Tumor - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Brain Tumor - Pipeline Review, H1 2014’, provides an overview of the Brain Tumor’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Tumor and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Brain Tumor
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Brain Tumor and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Brain Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Brain Tumor pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Brain Tumor
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Brain Tumor pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Brain Tumor - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Brain Tumor Overview 8
Therapeutics Development 9
Pipeline Products for Brain Tumor - Overview 9
Pipeline Products for Brain Tumor - Comparative Analysis 10
Brain Tumor - Therapeutics under Development by Companies 11
Brain Tumor - Therapeutics under Investigation by Universities/Institutes 13
Brain Tumor - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Brain Tumor - Products under Development by Companies 17
Brain Tumor - Products under Investigation by Universities/Institutes 18
Brain Tumor - Companies Involved in Therapeutics Development 19
Pfizer Inc. 19
Bayer AG 20
Hutchison MediPharma Limited 21
Advantagene, Inc. 22
Oncovir, Inc. 23
DEKK-TEC, Inc. 24
CalAsia Pharmaceuticals, Inc. 25
Tolero Pharmaceuticals, Inc. 26
Dong-A Socio Holdings Co Ltd 27
Brain Tumor - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 33
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
diaziquone - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Poly-ICLC - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
GliAtak - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
VAL-083 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
HMPL-813 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
DA-3607 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
DC/AAT + DC/AAT-Flu + DC/KLH - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Dendritic Cell Vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
CIGB-128 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
HOOI - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
TP-0903 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Neural Stem Cells - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Bispecific T-Cell Engager - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Bay-846 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
VO-101 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
PF-06463922 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Small Molecule To Inhibit Hsp90 Alpha and TRAP1 For Brain Cancer - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Antibody to Inhibit PGRN for Brain Tumor - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
Bi-specific Antibody For Brain Tumor Therapy - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Brain Tumor - Recent Pipeline Updates 63
Brain Tumor - Dormant Projects 68
Brain Tumor - Discontinued Products 69
Brain Tumor - Product Development Milestones 70
Featured News and Press Releases 70
Dec 16, 2013: Angiochem Demonstrates Peptide Antibody Conjugate That Successfully Crosses the Blood Brain Barrier and Increases Survival in HER-2 Positive Brain Tumors 70
Nov 16, 2013: Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress 70
Jun 03, 2013: DelMar Pharma Presents Additional Clinical Data From Ongoing Brain Cancer Study With VAL-083 At ASCO 2013 Annual Meeting 71
Mar 18, 2013: Anti-nausea Drug Halts Growth Of Brain Tumors, Research Finds 72
Dec 17, 2012: new immune therapy successfully treats brain tumors in mice 73
Aug 18, 2011: Cell Therapeutics Announces Enrollment Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors 74
Jun 06, 2011: CTI Announces Interim Results Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors 74
Feb 02, 2011: Antisense Pharma Receives Approval For Clinical Studies In South Korea And Taiwan In Malignant Brain Tumors 75
Nov 02, 2010: Antisense Pharma's Trabedersen In Malignant Brain Tumors: Phase IIb Data Published In Neuro-Oncology 76
Oct 29, 2010: Novartis Drug Afinitor Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis. 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80

List of Tables

Number of Products under Development for Brain Tumor, H1 2014 9
Number of Products under Development for Brain Tumor - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Brain Tumor - Pipeline by Pfizer Inc., H1 2014 19
Brain Tumor - Pipeline by Bayer AG, H1 2014 20
Brain Tumor - Pipeline by Hutchison MediPharma Limited, H1 2014 21
Brain Tumor - Pipeline by Advantagene, Inc., H1 2014 22
Brain Tumor - Pipeline by Oncovir, Inc., H1 2014 23
Brain Tumor - Pipeline by DEKK-TEC, Inc., H1 2014 24
Brain Tumor - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2014 25
Brain Tumor - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 26
Brain Tumor - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 27
Assessment by Monotherapy Products, H1 2014 28
Assessment by Combination Products, H1 2014 29
Number of Products by Stage and Target, H1 2014 32
Number of Products by Stage and Mechanism of Action, H1 2014 35
Number of Products by Stage and Route of Administration, H1 2014 37
Number of Products by Stage and Molecule Type, H1 2014 39
Brain Tumor Therapeutics - Recent Pipeline Updates, H1 2014 63
Brain Tumor - Dormant Projects, H1 2014 68
Brain Tumor - Discontinued Products, H1 2014 69

List of Figures

Number of Products under Development for Brain Tumor, H1 2014 9
Number of Products under Development for Brain Tumor - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 28
Number of Products by Top 10 Target, H1 2014 30
Number of Products by Stage and Top 10 Target, H1 2014 31
Number of Products by Top 10 Mechanism of Action, H1 2014 33
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 34
Number of Products by Top 10 Route of Administration, H1 2014 36
Number of Products by Stage and Top 10 Route of Administration, H1 2014 37
Number of Products by Top 10 Molecule Type, H1 2014 38
Number of Products by Stage and Top 10 Molecule Type, H1 2014 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Brain Cancer: Analytical Tool

Brain Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Glioblastoma Multiforme - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Cancer Statistics in the US

  • November 2016
    74 pages
  • Cancer  

  • United States  

View report >

Cancer Statistics and Therapy Market in the US - Forecast

  • November 2016
    52 pages
  • Cancer  

    Therapy  

  • United States  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.